Unlocking new possibilities for Central Nervous System (CNS) disease treatment, NEO100 is designed to potentially enable the enhanced delivery of vital therapeutics directly to the brain. This groundbreaking approach aims to maximize drug efficacy and improve patient outcomes.
Diverse Actions Needed for CNS Treatment
NEO100 comprises a patented composition of a proprietary synthesis of Perillyl Alcohol (POH) that our research suggests has several beneficial actions for Central Nervous System (CNS)-based disease applications, including:
- Regulates neurologic pathways associated with tumor cell growth.
- Bypasses the BBB via its small molecular size when delivered intranasally.
- Creates a temporary BBB opening when delivered intra-arterially, enabling larger molecule therapeutics to pass.
- Acts as an effective therapeutic for brain cancers in high concentrations.
- Serves as a solvent for traditional large-molecule therapeutics at low concentrations, allowing them to bypass the BBB.
- Can be conjugated with other CNS therapeutics to create compound formulations with higher BBB penetration and greater effect on brain cancer.
NEO100: Understanding Our Approach
Explore the essential details about NEO100, from its natural origins and unique properties
to its mechanism of action and various advanced delivery methods.
1. What is POH?
Perillyl Alcohol (POH) is a naturally occurring substance found in the essential oils of plants, such as citrus. It is already FDA-approved as a flavoring food agent.
POH has been shown to have antitumor activity against various cancer types including gliomas. POH induces apoptosis in tumor cells without affecting normal cells and can revert tumor cells to a differentiated state.
2. How does NEO100 work?
In the NEO100 Phase 1/2a trial, NEO100 has been shown to potentially positively impact the treatment of Grade IV gliomas. Grade IV gliomas are among the most aggressive and deadly forms of brain cancers, and patients with this form of cancer face a grim prognosis. Only a quarter of newly diagnosed Glioblastoma patients survive for 24 months, and fewer than 10 percent survive more than five years.
Because of its small lipophilic molecular size, NEO100 can permeate the Blood-Brain-Barrier and therefore allow delivery of itself or a combinatorial therapeutic directly to a tumor site.
3. How is NEO100 Administered?
Since our clinical trial and research has demonstrated that NEO100 potentially permeates across the Blood Brain Barrier (BBB), three forms of delivery can be used to administer NEO100 or any of its conjugates.
Internasal Delivery – NEO100 can be delivered intranasal through the trigeminal pathway to bypass the BBB. This ability allows NEO100 to be used for local targeted delivery to the brain eliminating the issues associated with oral and intravenous delivery methods.
Permeable BBB Delivery – Since NEO100 is a small, lipophilic (fat-soluble) molecule, it can permeate the BBB which primarily targets the restriction of entry for large molecule substances (pathogens, viruses) and water-soluble compounds.
Intra-Arterial Delivery – NEO100 can be delivered intrathecally through a catheter positioned in the arterial pathway which feeds the tumor and is injected into the tumor site where it would be absorbed through the BBB into the tumor.
Research & Clinical Findings
Discover over 48 groundbreaking clinical trials involving NEO100 and it's potential impact on CNS diseases.
Mechanism of Action
NeOnc’s ongoing research continues to deepen our understanding of POH’s mechanism of action (MOA). In pharmacology, a drug’s MOA describes the specfiic biochemical interactions, like binding to enzymes or receptors, through which it produces its effects on a targeted disease. The potential MOA of NEO100, detailing these crucial molecular interactions, is shown below:
